Mathys & Squire will be at TechBio UK 2026 on 13th October in London, UK.
Partner Philippa Griffin will be attending the UK BioIndustry Association (BIA)’s flagship TechBio conference in London.
TechBio UK will showcase innovative companies in areas such as genomics, bioengineering and AI-driven drug discovery, and will explore key issues for this sector, including how companies can seek the right investors and partners as they grow and how the UK can strengthen its leadership in TechBio.
TechBio refers to a technology-driven approach to biology, integrating AI, machine learning, automation and software systems to accelerate innovation across health delivery, advanced therapeutics, drug discovery and engineering biology. The specific combination of computational platforms with biological applications requires a unique and carefully considered approach to intellectual property management. At Mathys & Squire, our attorneys have extensive experience in helping companies at the cutting-edge of TechBio to protect their inventions. With specialist expertise spanning multiple disciplines, we are well-positioned to advise on the protection and commercialisation of innovation in this sector.
Philippa Griffin is a UK & European patent attorney with a strong track record in protecting biotech start-up inventions. Her specialist expertise sits across a wide range of technologies, including synthetic biology, gene editing, and sequencing; nucleic acid-based therapies and delivery technologies; antibodies and immunology, including immunotoxin-based therapeutics; recombinant protein production and formulation; diagnostic assays; cardiac biology; tissue regeneration; and vaccines. Philippa’s practice covers all aspects of drafting, prosecution, and portfolio management, as well as defending and challenging patents in EPO opposition and appeal proceedings.
For more information on the event, click here.
Contact our team
Philippa Griffin – Partner | [email protected]
